A Phase 1 interventional study of Ferumoxytol injection and Pharmacological ascorbate in Glioblastoma and Glioblastoma Multiforme, sponsored by Bryan Allen. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.
Sponsored by Bryan Allen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.
Among the 232 studies testing temozolomide in Glioblastoma, this one is the 177th largest by enrollment of the 221 interventional ones that give a count, is one of 3 that started in 2023, is one of 70 in phase 1, reaches primary completion later than 5 of the 34 other live ones, and was the 206th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 16+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
Rigel Pharmaceuticals · Sites in United States, Australia, Canada and 4 more countries
Ages 12–39
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 110 · Phase 2 140 · Phase 3 16 · Phase 4 2
First in 1997; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 41 across the 221 interventional studies. Of the 168 that completed or were terminated, 69 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 232 have an industry lead sponsor. The 10 most frequent:
Bryan Allen is the lead sponsor of 4 studies on the registry; none are open to participants now.
Bryan Allen has 2 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
4 of the studies testing temozolomide in Glioblastoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04019262John FlickingerShort Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma | 2026-12 |
| NCT04623931M.D. Anderson Cancer CenterChemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | 2026-12-31 |
| NCT07193654Second Affiliated Hospital, School of Medicine, Zhejiang UniversityStupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | 2027-04-01 |
| NCT06297512Iacopo SardiEvaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | 2027-11-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 232 studies testing temozolomide in Glioblastoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial evaluates adding ferumoxytol and pharamcologic ascorbate (vitamin C) to standard of care treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will receive ferumoxytol and pharmacologic ascorbate in addition to the standard treatment.
The initial, standard treatment for glioblastoma multiforme (GBM) involves maximum safe surgical resection followed by radiation combined with temozolomide (a chemotherapy pill you take by mouth).
Participants in this trial will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiation Phase * Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks. * Ferumoxytol: 512 g administered intravenously (IV) the day before radiation and then during weeks 5 to 6 of radiation therapy. * Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks) * Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first). Adjuvant Phase * Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles * Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle * Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of chemotherapy.
Drug: Ferumoxytol injection · Drug: Pharmacological ascorbate · Radiation: External beam radiation therapy · Drug: Temozolomide
Radiation Phase * Ascorbate: 87.5 g administered intravenously (IV) three times each calendar week for approximately 8 weeks. * Ferumoxytol: 512 g administered intravenously (IV) the day before radiation, about 1 week after dose 1, during weeks 5 to 6 of radiation therapy, and then a week after that (for a total of 4 ferumoxytol infusions). * Radiation: 61.2 Gray (given 1.8 Gray once daily, 5 days per week, for about 7 weeks) or 60 Gray (2.0 Gray once daily for 5 days per week for about 6 weeks) * Temozolomide: 75 mg/m2, taken orally, once daily, every day, for up to 49 days or until radiation is completed (whichever comes first). Adjuvant Phase * Temozolomide: 150 to 200 mg/m2, taken orally, once daily, for five days out of 28 days (where 28 days is one cycle of chemotherapy) for up to six cycles * Ascorbate: 87.5 g administered intravenously (IV) twice each calendar week of the cycle * Ferumoxytol: 512 g administered intravenously (IV) the first day of the first cycle of
Drug: Ferumoxytol injection · Drug: Pharmacological ascorbate · Radiation: External beam radiation therapy · Drug: Temozolomide
Ferumoxytol is an iron replacement product FDA approved for treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). This trial uses the FDA approved dosage (512 mg iron) for iron-deficiency anemia in CKD.
Also known as: Feraheme, Ferumoxytol
Intravenous ascorbate
Also known as: ASCOR, vitamin C, ascorbic acid
Photon based, focal radiation therapy delivered consistent with national guidelines, standard for treatment of GBM.
Also known as: EBRT, radiotherapy, VMAT
Temozolomide is a cytotoxic alkylating agent administered orally that penetrates well into the central nervous system. It is a standard-of-care treatment for GBM.
Also known as: Temodar, temozolomide capsule
Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs)
The recommended dose will be determined by incidence of dose limiting toxicities.
Time frame: From treatment day 1 through 12 weeks after completing radiation
Estimate Progression Free Survival (PFS)
Time (measured in months) to documented disease progression in MRI imaging as described by the RANO criteria.
Time frame: From treatment day 1 to disease progression, up to 16 months post-treatment
Estimate Overall Survival (OS)
Time to death from any cause.
Time frame: Time (measured in months) until death from any cause, up to 26 months post-treatment
Disease Response
Disease response and tumor measurements over time were assessed using Response Assessment in Neuro-Oncology (RANO) criteria in conjunction with the Neurologic Assessment in Neuro-Oncology (NANO) beginning 12 weeks after completion of radiation therapy, using radiation simulation MRI/CT as baseline. RANO disease response categories included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Tumor measurements obtained during radiographic assessment were incorporated into the overall RANO response evaluation.
Time frame: 12 weeks post-radiation
Number of Participants With Treatment-Related Adverse Events
Categorize and quantify adverse events using the Common Terminology Criteria for Adverse Events (v5). Treatment-related adverse events were categorized by toxicity type, including liver function, hematologic, and non-hematologic events. Participants were counted once per toxicity category if they experienced at least one treatment-related adverse event within that category during the study period.
Time frame: Up to 36 months post-radiation
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 7 | 9 |
| Completed | 6 | 6 |
| Not completed | 1 | 3 |
| Withdrew: Did not meet compliance | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Travel and time commitment restraints | 0 | 1 |
The recommended dose will be determined by incidence of dose limiting toxicities.
| Dose Limiting Toxicities | Cohort 1 | Cohort 2 |
|---|---|---|
| Number of Ferumoxytol-related Dose Limiting Toxicities (DLTs) | 2 | 0 |
Time (measured in months) to documented disease progression in MRI imaging as described by the RANO criteria.
| months | Cohort 1 | Cohort 2 |
|---|---|---|
| Estimate Progression Free Survival (PFS) | 8 (4 to 12) | 6 (4 to 16) |
Time to death from any cause.
| Months | Cohort 1 | Cohort 2 |
|---|---|---|
| Estimate Overall Survival (OS) | 12 (9 to 26) | 13 (7 to 19) |
Disease response and tumor measurements over time were assessed using Response Assessment in Neuro-Oncology (RANO) criteria in conjunction with the Neurologic Assessment in Neuro-Oncology (NANO) beginning 12 weeks after completion of radiation therapy, using radiation simulation MRI/CT as baseline. RANO disease response categories included complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Tumor measurements obtained during radiographic assessment were incorporated into the overall RANO response evaluation.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Progressive Disease (PD) | 1 | 1 |
| Complete Response (CR) | 0 | 0 |
| Stable Disease (SD) | 4 | 5 |
| Partial Response (PR) | 0 | 0 |
Categorize and quantify adverse events using the Common Terminology Criteria for Adverse Events (v5). Treatment-related adverse events were categorized by toxicity type, including liver function, hematologic, and non-hematologic events. Participants were counted once per toxicity category if they experienced at least one treatment-related adverse event within that category during the study period.
| participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Liver function | 5 | 6 |
| Hematologic | 5 | 6 |
| Non-Hematologic | 5 | 6 |
Collected over Adverse event data were collected from treatment initiation through 36 months post-radiation.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 5/6 (83.3%) | 1/6 (16.7%) | 6/6 (100%) |
| Cohort 2 | 4/6 (66.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 1/6 | 0/6 |
| SeizureNervous system disorders | 0/6 | 1/6 |
| Event | Cohort 1 | Cohort 2 |
|---|---|---|
| ConstipationGastrointestinal disorders | 3/6 | 6/6 |
| Dry mouthGastrointestinal disorders | 5/6 | 6/6 |
| ChillsGeneral disorders | 4/6 | 6/6 |
| FatigueGeneral disorders | 4/6 | 6/6 |
| Alanine aminotransferase increasedInvestigations | 2/6 | 6/6 |
| Lymphocyte count decreasedInvestigations | 5/6 | 6/6 |
| AnemiaBlood and lymphatic system disorders | 5/6 | 1/6 |
| NauseaGastrointestinal disorders | 5/6 | 4/6 |
| Aspartate aminotransferase increasedInvestigations | 4/6 | 5/6 |
| Platelet count decreasedInvestigations | 1/6 | 5/6 |
| Age, Categorical(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 5 | 10 |
| >=65 years | 1 | 1 | 2 |
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 59 (51 to 71) | 60 (52 to 68) | 59 (51 to 71) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 5 | 4 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 6 | 12 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 6 | 6 | 12 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| United States | 6 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data will be released publicly as per participant consent and IRB approval. Individual researchers should contact the research team for data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Study protocol and informed consent will be shared after primary completion. Statistical analysis plan will be shared with results reporting.
Access criteria: An IRB-stamped signed usage agreement will be required in addition to a data sharing agreement between the academic centers.
Ran from Feb 2023 to primary completion in May 2025, 26 months.
Results were first posted in Jul 2026, 1 year 2 months after primary completion.
Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's 26 months is below that.
Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ferrosoferric Oxide · Temozolomide